OncoAlert

🌐 Big news: The 6th OncoAlert 🚨Colloquium is NOW AVAILABLE IN YOUR LANGUAGE!! 🇪🇸🇮🇳🇵🇹🇮🇹🇫🇷🇺🇦🇯🇵🇲🇽🇸🇦🇷🇺and many more SPOKEN & WITH CAPTIONS in 1⃣8⃣Languages ALL VIDEOS HERE 👇👇oncoalert360.com/multi-language… Top oncology experts. Global reach. Zero barriers. Watch the 50-sec video to learn how #BreastCancer @hoperugo🇺🇸 @matteolambe🇮🇹 @Icro_Meattini🇮🇹 Dr. Roberto Salgado 🇧🇪 @ErikaHamilton9 🇺🇸 @DrSGraff 🇺🇸 @itrisabel🇪🇸 @ESSOnews @ElisaAgostinett 🇧🇪 @RebeccaDSing 🇸🇬 @LazarPo31787807 🇷🇸 #LungCancer @GlopesMd🇺🇸 @jillfeldman4 🇺🇸 @UmbertoMalapel1 🇮🇹 @BRicciutiMD 🇺🇸 @UOzkerim 🇹🇷 @DrMirallas🇺🇸 GU Oncology @brian_rini 🇺🇸 @declangmurphy 🇦🇺 @KidneyCancer🇺🇸 @salvolarosa @Silke_Gillessen🇨🇭 @RenuEapen🇦🇺 @nataliagandur 🇦🇷 @seanmcbride 🇺🇸 @jAvallejo 🇪🇸@GuardConsortium GI Oncology @BenWestphalen 🇩🇪 @graokane 🇮🇪 @GIMedOnc🇺🇸 @NiuSanford 🇺🇸 @ARosen380 🇺🇸 @Erman_Akkus 🇹🇷 @realbowtiedoc 🇺🇸 GynOnc @NicoloBizzarri 🇮🇹Vanda Salutari 🇮🇹 @AStrojnaMD 🇩🇪Alejandra Martinez 🇫🇷 @CoquardRay 🇫🇷Christina Fotopoulou 🇬🇧Giorgia Garganesse 🇮🇹 @ChargariC 🇫🇷 @PaulJiL H&N🇬🇧 @DrJasonWestin Lymphoma🇺🇸 @FadiHaddad_MD Leukemia🇺🇸 @Abdallah81MD Multiple Myeloma🇺🇸 @NassifElise Sarcoma 🇺🇸 @DrBetofMDPhD Melanoma🇺🇸 Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg Our Collaborators @APCCC_Lugano @gu_onc @Uromigos and more and more to come.......

Bireociclib + fulvestrant significantly improves PFS vs placebo in endocrine-resistant HR+ advanced breast cancer (HR ~0.5). Another strong CDK4/6-era signal. #BreastCancer #Oncology @larvol @OncoAlert

The number of cancer survivors is rising, and so is the need for focused research. Explore the @AmericanCancer Journals' virtual collection on survivorship research, including statistics, care planning, and long-term outcomes. 🔗 acsjournals.onlinelibrary.wiley.com/doi/toc/10.332… @OncoAlert

📌 Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression The BRIGHT-2 Phase 3 Randomized Clinical Trial 🔗 jamanetwork.com/journals/jamao… @OncoAlert #OncoAlertAF @JAMAOnc 👉🏻 In this phase 3 randomized clinical trial including 305 patients, bireociclib plus fulvestrant prolonged median progression-free survival compared with placebo (14.7 months vs 7.3 months) in patients with HR-positive, ERBB2-negative ABC after endocrine progression.

🧬✨ POLE-mutated endometrial cancer → ultramutated biology & excellent survival 🌟 ➡️ Molecular confirmation is key ➡️ Enables safe treatment de-escalation 🎯 🔗 bit.ly/4bTxUBF @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88 #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

📌 Impact of Trastuzumab Deruxtecan (T-DXd) and Brain Stereotactic Radiosurgery on Intracranial Control and Radionecrosis Risk in HER2-Positive or -Low Breast Cancer Brain Metastases 🧠 🔗 thebreastonline.com/article/S0960-… @OncoAlert #OncoAlertAF @TheBreastOnline 🔸 T-DXd combined with SRS is not associated with an increased risk of radionecrosis. 🔹T-DXd and SRS is associated with improved intracranial control outcomes. 🔸T-DXd is associated with decreased local and distant brain failure. 🔹T-DXd plus SRS could be a safe and effective strategy for HER2+ or low BCBM. Further prospective investigations are warranted to validate these results and optimize treatment sequencing.

Aspirin & cancer prevention—myth or fact? 🤔 A @JAMAOnc paper👉 doi:10.1001/jamaoncol.2025.6196 In adults ≥70, 4.7 yrs of low-dose aspirin didn’t lower cancer risk and may increase cancer-related deaths during treatment. No long-term benefit seen. @OncoAlert #cancer #oncology

Attending #APOS2026? Consider CANCER as the home for your next #PsychosocialOncology research article. Hear from our Section Editor, Jennifer Knight, MD, MS, on priorities for submissions. Why submit: acsjournals.onlinelibrary.wiley.com/journal/109701… Full video: youtu.be/p1e26eIl754 @OncoAlert

New in-depth review discusses the principles of neoadjuvant #immunotherapy for cutaneous #melanoma and invasive cutaneous squamous cell carcinoma. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert CC: @diwakardavar @MelanomaReAlli @CureMelanoma

Thank you @ASCOPost for this interview about #Litespark022, the first + study of combo in adjuvant Kidney Cancer ! @montypal, @DrRanaMcKay @DrRosenbergMSK we need to update @AUC3_Official ! Data presented #GU26 @ASCO @OncoAlert ascopost.com/news/march-202…

The #OncoAlertColloquium 2026 GYN Malignancies🚨 ESGO SESSION Presentation by Dr. Nicolò Bizzarri🇮🇹 : Year in Review Surgical #CervicalCancer REGISTER HERE TO WATCH: buff.ly/xwD5G2D Surgical trials for cervical cancer in 2025 focused on de-escalation of surgical radicality. In particular, the SENTIX and PHENIX trials showed the oncological safety of sentinel lymph node (SLN) alone. The GOG278 study demonstrated the efficacy and safety of conservative surgery in low-risk disease. 📊 Sub-analyses of the SHAPE trial generated hypotheses supporting the potential safety of a minimally invasive approach to simple hysterectomy, as well as the safety of conization prior to hysterectomy. The LASH trial is ongoing and will further assess the oncologic safety of minimally invasive simple hysterectomy in low-risk cervical cancer. ⏳ GynOnc @NicoloBizzarri 🇮🇹 Vanda Salutari 🇮🇹 @AStrojnaMD 🇩🇪 Alejandra Martinez 🇫🇷 @CoquardRay 🇫🇷 Christina Fotopoulou 🇬🇧@CF_PC_OvCaGroup Giorgia Garganesse 🇮🇹 Ms. Anne De Middelaer @EngageEsgo @agz_eriksson @womenofteal #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

News From Industry: TALAPRO Update in #ProstateCancer Source Businesswire and Pfizer buff.ly/HTeEtmv Pfizer reports the Phase 3 TALAPRO-3 trial showed that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in patients with HRR-mutated metastatic hormone-sensitive prostate cancer, exceeding the target hazard ratio. Benefits were consistent across BRCA and non-BRCA mutations. An interim analysis indicated a strong trend toward improved overall survival. @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @nataliagandur @acampsmalea @BRicciutiMD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago

Just in: The phase 3 Talapro-3 trial met its primary endpoint!!! fiercepharma.com/pharma/pfizer-… @OncoAlert @AUC3_Official

🆙 #ELCC26 @myESMO 🇩🇰 🔥Proffered Paper session 1 ☑️iza-bren (BL-B01D1) + serplulimab in SCLC 🎯ORR 88.3%, mPFS 8.2m, 12m OS rate 80.8% 🎙️Dr. Fei Zhou 🎙️Chair: @peters_solange 📍NCT06437509 @OncoAlert @Larvol #LCSM

🆙 #ELCC26 @myESMO 🇩🇰 🔥Proffered Paper session 1 ☑️Obrixtamig + ezabenlimab in SCLC or NECs 🎯Overall: ORR 30%, DCR 58%, mPFS 4.4m 🎯Highest dose: ORR 58%, DCR 83%, mPFS 10m 🎙️ @JulienMazieres 🎙️Chair: @peters_solange 📍NCT05879978 @OncoAlert @Larvol #LCSM

🆕 Just published 📰🗞️👇🏽 What intrigued me most about going into oncology was the power of one’s own body to fight #cancer. Immunotherapy🙌🏽 Important to publish real🌍cases. Off-label; durable🗓️➕#ctDNA📉🟰CURES🤞🏽 Rego💊➕PD1/CTLA4⛔️ @OncoAlert #CRCSM journals.sagepub.com/doi/10.1177/17…

#ColorectalCancer incidence and mortality continue to decline in adults ≥65, decreasing by >2% per year. However, rectal cancer incidence increased 1% per year across all ages from 2019–2022, reversing decades of decline. More stats: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @OncoAlert #CRCSM

@lh_innovations @OncoAlert Here’s a nice recent paper 📑 on the mechanistic insights of this regimen. @AACR As well as long term outcomes article. 💡Patients with MSS non-liver metastatic (NLM) #colorectalcancer tend to do better. 🆕 biomarker/subset - NLM. @OncoAlert aacrjournals.org/cancerimmunolr…

Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy onlinelibrary.wiley.com/doi/10.1111/ca… Comprehensive genomic profiling in localized #ProstateCancer identified alterations in six genes🧬 (PTEN, BRCA2, POLD1, ERBB3, MYC, SETD2) associated with biochemical recurrence and worse recurrence-free survival after prostatectomy. Alteration-positive patients showed higher stage and recurrence rates. BRCA2, especially with SETD2 co-alteration, predicted poorer outcomes. These findings suggest genomic profiling may refine risk stratification, though further validation is needed before guiding management in localized disease. @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2 aacrjournals.org/clincancerres/… NF2 loss in renal cell carcinoma defines an aggressive subtype with frequent metastases and poor outcomes. In a cohort of 33 patients, non-immunotherapy regimens showed numerically longer survival than immunotherapy, though not statistically significant. Genomic analyses revealed frequent NF2 mutations and alterations in cell cycle and DNA repair pathways. Transcriptomic data showed increased proliferation and immune suppression, highlighting limited immunotherapy efficacy and the need for molecularly tailored treatment strategies. #KidneyCancer @yekeduz_emre @WeiweiBian @MarcMachaalani @Mustafajsalehmd @eddy_saad @Clara__Steiner @bergsa83 @BradMcG04 @CharleneMantia @PrafulRavi1 @VincentWenxinXu @MichelleDunno17, @DrChoueiri @MikeSerzanMD @OncoAlert 🚨

HER2+ leptomeningeal metastasis = one of the worst prognoses in oncology. But TBCRC049 gives a real signal of hope. 🎯 🧪 Phase 2 (single-arm) Tucatinib + Trastuzumab + Capecitabine in newly diagnosed HER2+ LM 📊 Results: 📈 Median OS: 10 months ⏳ CNS progression: 6.9 months 🎯 LM response: 38% ✨ Neuro improvement: 58% 💡 Why this matters: Historical survival ~4–5 months → this is a meaningful shift ⚠️ Caveats: Small (n=17), no control arm, early closure 🧩 Takeaway: CNS-active HER2 targeting may finally change outcomes in LM 🔖 Save this - rare but practice-relevant scenario 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #BreastCancer #HER2 @OncoAlert @myesmo @esmo_open @asco